[Second-line treatment of malignant pleural mesothelioma with Pemetrexed (Alimta) -- a case report]. / Second-line-Behandlung des malignen Pleuramesothelioms mit Pemetrexed (Alimta) -- eine Kasuistik.
Pneumologie
; 59(2): 108-11, 2005 Feb.
Article
en De
| MEDLINE
| ID: mdl-15724224
Malignant Pleural Mesothelioma is regarded as a tumour, which lacks chemo-sensitivity. However, patients are able to benefit from a first line chemotherapy, as indicated in a currently published randomised study. Here the case of a 75 year old patient will be reported, who has been diagnosed with malignant pleural mesothelioma for 4 years. After a first line therapy with Gemcitabine/Oxaliplatin, partial remission was assessed. 15 months later a distinct progress was detected. After a second line therapy with Pemetrexed a sound partial response could be determined radiologically and clinically. This case history is supposed to exemplify that patients with malignant pleural mesothelioma should not only be considered for a first line therapy, but that a second line therapy may also be offered to a certain group of patients. The new substance Pemetrexed (Alimta) offers an excellent alternative with a very good efficacy profile and a favourable spectrum of side effects.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Pleurales
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Desoxicitidina
/
Glutamatos
/
Guanina
/
Mesotelioma
/
Antimetabolitos Antineoplásicos
Tipo de estudio:
Clinical_trials
Límite:
Aged
/
Humans
/
Male
Idioma:
De
Revista:
Pneumologie
Año:
2005
Tipo del documento:
Article
Pais de publicación:
Alemania